Shionogi to acquire US biopharma IntraBio for about $2 billion
In short
Shionogi announced on Oct. 5 that it will acquire US biopharmaceutical company IntraBio, based in Texas, for $2 billion (about ¥315.5bn) and make it a wholly owned subsidiary. The company said the deal strengthens its rare disease business and brings intellectual property and global sales rights to IntraBio’s neurological rare disease drug AQNEURSA. Completion is targeted for November–December 2026, subject to regulatory approval.
Read the full story 1 min read
Shionogi said on Oct. 5 that it will acquire US biopharmaceutical company IntraBio, which is based in Texas, for $2 billion. TBS put the yen value at about ¥315.6bn, Asahi and Yahoo! News at about ¥315.5bn and Nikkei at about ¥314bn. [ 1 , 2 , 3 , 4 ]
The buyer will take all of IntraBio’s outstanding shares and make the company a wholly owned subsidiary through Shionogi’s US group company Shionogi Inc., according to Nikkei and Yahoo! News; Asahi described Shionogi itself as the acquirer. The purchase is planned for November–December 2026, subject to regulatory approvals, the outlets reported. [ 2 , 3 , 4 ]
Asahi reported that IntraBio develops treatments for neurological symptoms of the rare disease Niemann-Pick disease type C, which involves gait disturbance and cognitive decline, and that Shionogi described the deal as a way to strengthen its rare disease field, including by gaining personnel and know-how. Nikkei reported that the acquisition covers the intellectual property and global sales rights to AQNEURSA, IntraBio’s drug for a neurological rare disease, and that Shionogi aims to use sales channels gained from large acquisitions it has pursued since 2025 to make rare disease drugs a growth pillar. [ 2 , 3 ]
Yahoo! News, citing Reuters, reported that Shionogi will make IntraBio a wholly owned subsidiary and secure all rights to the rare disease drug AQNEURSA. Nikkei said AQNEURSA has approvals in Europe and the US, without giving further detail in the available text. [ 3 , 4 ]
Why it matters
The purchase adds a US rare disease drug and its global rights to a Japanese drugmaker’s pipeline, a segment Nikkei reported Shionogi is positioning as a growth pillar. Because the deal needs regulatory clearance and is not due to close until late 2026, its commercial effect will not be visible immediately. Beyond the companies involved, the documents give no basis for a wider impact.
Key facts
- Shionogi announced on Oct. 5 that it will acquire US biopharmaceutical company IntraBio, based in Texas. [ 1 , 2 , 3 , 4 ]
- The purchase price is $2 billion; Japanese outlets converted this to about ¥315.5bn (Asahi, Yahoo! News), ¥315.6bn (TBS) and ¥314bn (Nikkei). [ 1 , 2 , 3 , 4 ]
- Shionogi will acquire all outstanding shares and make IntraBio a wholly owned subsidiary through its US group company Shionogi Inc. [ 2 , 3 , 4 ]
- Completion is planned for November–December 2026, subject to regulatory approval. [ 2 , 4 ]
- IntraBio develops treatments for neurological symptoms of the rare disease Niemann-Pick disease type C, which involves gait disturbance and cognitive decline. [ 2 ]
- The deal covers intellectual property and global sales rights to IntraBio’s neurological rare disease drug AQNEURSA. [ 3 , 4 ]
Confirmed by several sources
Still unclear
- The yen value of the deal differs between outlets, from about ¥314bn to about ¥315.6bn. Nikkei gives about ¥314bn, Asahi and Yahoo! News about ¥315.5bn and TBS about ¥315.6bn; the documents do not explain the difference.
- Whether Shionogi itself or its US subsidiary is the direct acquirer. Asahi says Shionogi will acquire IntraBio, while Nikkei and Yahoo! News say the purchase will be made through a US group company or subsidiary.
- Details of AQNEURSA’s approvals and commercial status. Only Nikkei mentions that the drug has approvals in Europe and the US, and its article is cut off at that point.
- Completion is targeted for November–December 2026, conditional on regulatory approval. Reported by a single source so far
What local media are saying
Timeline, local time
- TBS reports Shionogi’s announcement that it will acquire US IntraBio for about ¥315.6bn. [ 1 ]
- Asahi reports the $2bn (about ¥315.5bn) all-share purchase and the November–December completion target. [ 2 ]
- Nikkei reports the deal at about ¥314bn and the acquisition of AQNEURSA rights through a US subsidiary. [ 3 ]
- Yahoo! News relays a Reuters report on the wholly owned subsidiary and the ¥315.5bn price. [ 4 ]